New injection targets skin tumors before surgery in early trial

NCT ID NCT06014086

Ongoing Disease control Sponsor: Phio Pharmaceuticals Inc. Source: ClinicalTrials.gov ↗

First seen Dec 31, 2025 · Last updated May 13, 2026 · Updated 25 times

Summary

This early-phase trial tests a drug called PH-762, injected directly into skin tumors in people with squamous cell carcinoma, melanoma, or Merkel cell carcinoma. The goal is to see if it is safe and how the body and tumors respond. About 30 participants will receive four weekly injections into one tumor, followed by surgical removal of the tumor about two weeks later.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SQUAMOUS CELL CARCINOMA OF THE SKIN are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Banner MD Anderson Cancer Center

Gilbert, Arizona, 85234, United States
Centricity Research

Columbus, Ohio, 43213, United States
Integrity Research

Delray Beach, Florida, 33445, United States
Paradigm Clinical Research

San Diego, California, 92108, United States
Skin Cancer and Dermatology Institute

Reno, Nevada, 89509, United States

Conditions

Explore the condition pages connected to this study.

MALIGNANT MELANOMA OF SKIN MERKEL CELL CARCINOMA OF SKIN SQUAMOUS CELL CARCINOMA OF THE SKIN